State of Alaska Department of Revenue Has $1.29 Million Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

State of Alaska Department of Revenue boosted its position in shares of Azenta, Inc. (NASDAQ:AZTA) by 355.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,899 shares of the company’s stock after purchasing an additional 20,210 shares during the quarter. State of Alaska Department of Revenue owned 0.06% of Azenta worth $1,294,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in shares of Azenta by 20.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after buying an additional 256 shares during the period. KBC Group NV lifted its holdings in Azenta by 48.5% during the fourth quarter. KBC Group NV now owns 2,137 shares of the company’s stock worth $107,000 after acquiring an additional 698 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Azenta in the fourth quarter valued at about $200,000. Net Worth Advisory Group bought a new stake in shares of Azenta in the third quarter worth about $205,000. Finally, Aigen Investment Management LP bought a new stake in shares of Azenta in the third quarter worth about $214,000. Institutional investors own 99.08% of the company’s stock.

Insider Buying and Selling at Azenta

In other Azenta news, CFO Herman Cueto sold 712 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total transaction of $28,529.84. Following the transaction, the chief financial officer now owns 23,892 shares of the company’s stock, valued at $957,352.44. The trade was a 2.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William L. Cornog acquired 12,500 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $39.60 per share, with a total value of $495,000.00. Following the acquisition, the director now owns 14,755 shares in the company, valued at $584,298. The trade was a 554.32 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 1,423 shares of company stock worth $57,020. Insiders own 10.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on AZTA. Needham & Company LLC lifted their price objective on Azenta from $55.00 to $59.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Azenta in a research note on Thursday, January 2nd. Finally, Evercore ISI increased their price objective on shares of Azenta from $50.00 to $52.00 and gave the stock an “in-line” rating in a research report on Thursday, February 6th.

Azenta Price Performance

AZTA stock opened at $45.32 on Thursday. The business has a 50-day moving average of $50.56 and a 200-day moving average of $48.74. Azenta, Inc. has a fifty-two week low of $38.82 and a fifty-two week high of $67.77. The stock has a market capitalization of $2.07 billion, a P/E ratio of -15.21 and a beta of 1.47.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. Equities analysts expect that Azenta, Inc. will post 0.42 EPS for the current year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.